Other

Shandong University

Bloomage Biotechnology Corporation Limited

Bloomage Freda Biopharm Co., Ltd.

Xueping Guo

Jie Liu

Yan Xi Jin

Peixue Ling

Fengshan Wang

Ning Feng

Yanli He

Jianying Chen

Juzheng Sheng

Wei Xue

Zhen Lu

Yuanjun Sun

Liping Qiao

Yihong Luan

Liu Sun

Haina Li

Jianqun Deng

Yanli Shi

Ranran Du

Haiying Wang

Aihua Liu

Guanfeng Wang

Tianmin Zhang

A heparin skeleton synthase originates from, with an amino acid sequence as shown in SEQ ID NO.2 and a nucleotide sequence of the coding gene as shown in SEQ ID NO.1. Its recombinant expression level is 6.8 times that of the existing heparin skeleton synthase KfiA fromK5, and total enzyme activity per fermentation liquor is 5.22 times that of the heparin skeleton synthase KfiA. The heparin skeleton synthase mutants obtained through site-directed mutagenesis of the sites No. 16, No. 25, No. 30, No. 111, No. 165, and No. 172 in the amino acid sequence of the said heparin skeleton synthase all have high expression levels.

Heparin skeleton synthase and its mutants and application

The present invention provides asp. having a deposit access number of CGMCC NO. 5744 and a hyaluronidase produced by theand the amino acid sequence of the hyaluronidase is shown in SEQ ID NO: 2. The present invention further relates to a process for preparing oligomeric hyaluronic acid or salts thereof or low-molecular-weight hyaluronic acid or salts thereof by using theor the hyaluronidase produced thereby. The produced oligomeric hyaluronates or low-molecular-weight hyaluronates have advantages such as good transdermal absorption ability, high purity, no cytotoxicity, potent antioxidant ability. The present invention also provides use of thehaving a deposit access number of CGMCC NO. 5744, or the hyaluronidase, oligomeric hyaluronates or salts thereof, low-molecular-weight hyaluronates or salts thereof produced by thein the fields of osmetics, food products and medicines.

Bacillus, hyaluronidase, and uses thereof

The present invention discloses a bismuth hyaluronate, characterized in that the bismuth content is from 0.5% to 40%, and the glucuronate content is from 20% to 45%, based on dry weight. Also provided is a method for the preparation of said bismuth hyaluronate comprising reaction of a soluble hyaluronate salt with a bismuth salt in a basic aqueous solution, followed by steps of precipitation, filtration, desalting, dehydrating and drying to obtain the product. Further disclosed is the use of the bismuth hyaluronate in the manufacture of a medicament or health foods for preventing and treating gastrointestinal disorders, in particular ulcerous disorders of the GI tract. It has been proven in animal experiments to show a better therapeutic effect than products of the same type.

Bismuth hyaluronate, the preparation method and the use thereof

Growing community of inventors

Jinan, China

Xueping Guo